

**Supplementary Table 9.** Risk of MACE in individuals who received the herpes zoster (HZ) vaccine compared to those who did not, with vaccination administered more than one year after a diabetes mellitus diagnosis.

	Exposure group		Comparison		HR (95% C.I.)
	N	No. of event	N	No. of event	
<b>Any HZ vaccine vs no HZ vaccine</b>					
<b>(N1 matched population)</b>					
MACE	138,083	17,009	138,083	27,096	0.58 (0.57–0.59)
Coronary artery disease	138,083	6,313	138,083	8,772	0.67 (0.65–0.69)
Stroke	138,083	5,999	138,083	7,656	0.74 (0.71–0.76)
All-cause mortality	138,083	8,027	138,083	16,215	0.48 (0.46–0.49)
<b>Shingrix vs no HZ vaccine</b>					
<b>(N2 matched population)</b>					
MACE	45,904	5,063	45,904	9,926	0.62 (0.60–0.65)
Coronary artery disease	45,904	1,970	45,904	3,241	0.75 (0.71–0.80)
Stroke	45,904	1,831	45,904	2,831	0.79 (0.74–0.84)
All-cause mortality	45,904	2,180	45,904	5,965	0.48 (0.46–0.51)
<b>Zostavax vs no HZ vaccine</b>					
<b>(N3 matched population)</b>					
MACE	33,350	8,024	33,350	6,280	0.61 (0.59–0.63)
Coronary artery disease	33,350	2,980	33,350	2,014	0.71 (0.67–0.75)
Stroke	33,350	3,072	33,350	1,805	0.82 (0.77–0.87)
All-cause mortality	33,350	3,995	33,350	3,751	0.48 (0.46–0.50)
<b>Shingrix vs Zostavax</b>					
<b>(N4 matched population)</b>					
MACE	27,171	2,259	27,171	6,916	0.99 (0.94–1.04)
Coronary artery disease	27,171	900	27,171	2,555	1.08 (0.99–1.17)
Stroke	27,171	852	27,171	2,601	0.97 (0.89–1.06)
All-cause mortality	27,171	851	27,171	3,556	0.91 (0.84–0.99)

Any HZ vaccine: Shingrix or Zostavax; MACE: major adverse cardiovascular events; HZ: herpes zoster